Endpoint: Definition and additional resources from BNET
On TechRepublic: 19 words you don't want in your resume

BNET Business Dictionary

Business Definition for: Endpoint

  • a point at which a definable event in a study takes place, for example, the recovery of a patient in a medical study

Additional Resources

CheckClear's Endpoint Exchange Network - Metcalfe's Law in Action
This paper introduces CheckClear's Endpoint Exchange Network, which is a national network through which financial institutions can send and exchange check images rather than paper checks for clearing and settlement. The Endpoint Exchange Network's use of imaging technology, and managed frame relay replace the high costs of trucks and planes...
Tags: NETWORKING, frame relay, imaging, financial, network
White papers 2003-11-11
Endpoint Security for Protecting Data on Mobile Computers
The increased use of laptop computers and mobile devices has fueled an unprecedented number of data breaches. For IT departments, even encryption technology and strong corporate policy cannot prevent data breaches resulting from careless use of laptops by end users. Endpoint security lets you remotely delete...
Tags: PRODUCTIVITY, Notebooks, Absolute Software, mobile computer, encryption technology, data security, data protection, sensitive information, laptop computer, mobile, computer, mobile device, LAN
White papers 2008-03-06
Millennium Announces Phase II Data for MLN02 in Crohn's Disease
In this article Millennium Pharmaceuticals, Inc. discusses their results of a randomized, placebo-controlled phase II trial of MLN02 (formerly known as LDP-02) in patients with Crohn's disease. The study found that the primary endpoint of the trial, a decrease of greater than 70 points on the Crohn's Disease Activity Index...
Tags: Millennium Pharmaceuticals Inc., endpoint, patient
White papers
New Data Reveal Clinical Differences Between INTEGRILIN (Eptifibatide) Injection and Bivalirudin
In this article Millennium Pharmaceuticals, Inc. discusses the results of the PROTECT trial, which was designed to compare the glycoprotein GP IIb-IIIa inhibitor INTEGRILIN with the direct thrombin inhibitor bivalirudin in high risk patients using clinical and physiologic endpoints. On the physiologic primary endpoint of coronary flow reserve CFR, a...
Tags: Millennium Pharmaceuticals Inc., endpoint, patient
White papers 2004-11-06
Millennium Announces VELCADE (Bortezomib) for Injection has Significantly Extended Survival in Phase III (APEX) Trial of Patients With Relapsed Multiple Myeloma
In this article Millennium Pharmaceuticals, Inc. discuses their final survival endpoint analysis in the phase III confirmatory APEX study comparing patients receiving VELCADE to those receiving high-dose dexamethasone, VELCADE produced a statistically significant survival benefit. The study was designed to include survival as a secondary endpoint and allowed crossover for...
Tags: Millennium Pharmaceuticals Inc., VELCADE, patient, analysis
White papers
Independent Committee Recommends Early End to Confirmatory Phase III VELCADE Trial Based on Achieving Statistically Significant Improvement in Primary Endpoint
In this article, Millennium Pharmaceuticals, Inc informs that the company, based on the recommendation of an independent data monitoring committee and the notification of regulatory authorities, is halting the control arm in the phase III APEX trial. This allows patients currently receiving dexamethasone the option to immediately crossover to VELCADE...
Tags: Millennium Pharmaceuticals Inc., VELCADE, endpoint, patient, therapy, analysis
White papers
AMAG's Iron Replacement Therapy: Great Potential, Problematic Trial
A. Reza Saadat submits: On May 31st, AMAG Pharmaceutical AMAG announced results from a randomized phase III study of Ferumoxytol, an intravenous [IV] iron replacement therapy, in 31 patients with chronic kidney disease [CKD] stages 1-5 with functioning kidney transplants. The primary endpoint was the mean change in hemoglobin...
Tags: Biotech, AMAG Pharmaceuticals Inc.
External links 2008-06-30
Budget Windows, Sunsets, and Fiscal Control
Governments around the world have struggled to find the right method of controlling public spending and budget deficits. In recent years, the United States has evaluated policy changes using a ten-year budget window. The use of a multi-year window is intended to capture the future effects of policies, the notion...
Tags: Construction, National Bureau of Economic Research, window
White papers 2004-08-01
Trends in Enterprise Print: Understanding the Cost of Business Communications
A critical step in developing an integrated business communication strategy is to establish a highly accessible common repository for core content. The endpoint vision for an effective business communications strategy is a cross media model. In such a model, the content is developed by various content owners, independent from the...
Tags: vision, business process
White papers 2006-03-12
Use of Pulse Oximetry in Automated O2 Delivery to Ventilated Infants
Oxygen delivery to premature and/or critically ill infants should be closely controlled to achieve adequate tissue oxygenation while minimizing side effects. O2 therapy usually occurs by manual adjustments against a desired pulse oximeter SpO2 range. Some pulse oximeters have a history in neonates of alarming falsely, causing many clinicians to...
Tags: Masimo, therapy, O2 Plc., oxygen, adjustment, patient
White papers 2002-04-25
In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo
In this article Millennium Pharmaceuticals, Inc. discusses the results of a phase II trial of its investigational drug MLN02 in patients with ulcerative colitis, which showed statistically significant improvements in the clinical remission rates of patients treated with MLN02 compared to placebo, the trial's primary endpoint. MLN02 is an investigational,...
Tags: Millennium Pharmaceuticals Inc., patient
White papers
Understanding the Vacation Paradox
Parkinson's Law states that your workload will expand to whatever time you allocate for its completion. Thus, when you're willing to work late or to check on work stuff from your PDA at home, you're usually not really getting more done; instead, you're just being more wasteful with your time. That's...
Tags: David Goldenberg, Parkinson
Blog posts 2007-07-30
Exposing One of PR's Dirty Little Secrets
Chris Anderson, the editor-in-chief of Wired Magazine and author of "The Long Tail," ignited an online PR firestorm recently by posting a list on his blog of 300 PR people who had sent him unsolicited and unwanted PR pitches, saying that he had unilaterally and permanently added them to his...
Tags: Blogging, Jon Greer, public relations, Anderson
Blog posts 2007-11-08
Merck, Schering Unable to Stop Digging in Vytorin Mess
As an example of how not to handle a corporate crisis, it's hard to beat the growing scandal over Vytorin. That's the blockbuster anti-cholesterol drug whose clinical-trial data Merck and Schering-Plough sat on for a year or two after it showed that Vytorin was apparently no better than a...
Tags: Merck & Co. Inc., Vytorin, House Committee, Sales Strategy, E-mail, Healthcare, Sales, Online Communications, David P. Hamilton
Blog posts 2008-04-14
FDA to Biotech: Don't Blame Us For Your Cruddy Data
For the past few years, a coterie of biotech executives, desperate patients and ideologues have waged a low-level but steady campaign to convince the country that the Food and Drug Administration is condemning sick Americans to death by denying them potentially life-saving cancer drugs and other treatments. For all three,...
Tags: FDA, Patient, Drug, Richard Pazdur, Federal Government, Biotechnology, Government, David P. Hamilton
Blog posts 2008-05-29
Is Merck Hanging Schering Out to Dry on Vytorin?
Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
Tags: HEALTHCARE, Schering, Vytorin, ENHANCE Trial, Merck & Co. Inc., Zocor
Discussion threads 2008-07-07
Schering-Plough Now in the Feds' Crosshairs
Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
Tags: HEALTHCARE, Schering-Plough Corp., Schering, ENHANCE Trial, Vytorin, Zocor, trial result, Merck & Co. Inc.
Discussion threads 2008-07-10
How Pharma Stacks the Deck with Medical Journals
How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
Tags: HEALTHCARE, Schering, ENHANCE Trial, Vytorin, Zocor, trial result
Discussion threads 2008-06-18
Using Action Learning
Reg Revans (19072003) pioneered Action Learning as a management and organizational development tool. Its based on the premise that people learn best when they focus on a problem together. By sharing their prior knowledge and experience and by asking good questions based upon what they dont know, people can both...
Tags: BNET Editorial, knowledge, knowledge base, team, development tool, tool, environment, industry, benefit
Articles 2008-01-03
advertisement